Ascendis Pharma A/S ASND.OQ, ASND.O is expected to show a fall in quarterly revenue when it reports results on February 12 for the period ending December 31 2024
The Hellerup Denmark-based company is expected to report a 19.3% decrease in revenue to €111.178 million from €137.7 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
LSEG's mean analyst estimate for Ascendis Pharma A/S is for a loss of €1.08 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Ascendis Pharma A/S is $196.00, above its last closing price of $120.87.
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -1.76 | -1.74 | -1.72 | Beat | 1.2 |
Jun. 30 2024 | -1.34 | -1.38 | -1.91 | Missed | -38.1 |
Mar. 31 2024 | -1.46 | -1.50 | -2.30 | Missed | -53.1 |
Dec. 31 2023 | -1.98 | -2.03 | -1.54 | Beat | 24 |
Sep. 30 2023 | -2.32 | -2.38 | -2.88 | Missed | -21.1 |
Jun. 30 2023 | -2.57 | -2.59 | -2.16 | Beat | 16.6 |
Mar. 31 2023 | -2.65 | -2.66 | -1.98 | Beat | 25.6 |
Dec. 31 2022 | -2.44 | -2.56 | -3.70 | Missed | -44.5 |
This summary was machine generated February 10 at 21:46 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。